The efficacy results of the major CAR T-cells in development have been very positive. In this interview, Jeremy Abramson, MD, of Massachusetts General Hospital, Boston, MA, emphasizes the take-home message of what we have learned from the latest CAR T-cell studies. Dr Abramson also discusses the differences in the toxicity profiles of the main CAR T-cell therapies and what may cause this, in addition to the reversibility of the toxicities. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Take-home message on CAR T-cell therapy for lymphoma from ASH 2017
